Alphabet launches Isomorphic Laboratories to pursue AI-first drug discovery

Alphabet launches Isomorphic Laboratories to pursue AI-first drug discovery.

Alphabet has founded Isomorphic Laboratories, a company that uses artificial intelligence to discover new medicines. It is led by Demis Hassabis, the chief executive of the DeepMind lab.

Thrilled to announce the launch of a new Alphabet company @IsomorphicLabs. Our mission is to reimagine the drug discovery process from first principles with an AI-first approach, to accelerate biomedical breakthroughs and find cures for diseases. Details: https://t.co/WQrG36ddgZ pic.twitter.com/RRV6VeDhpL

— Demis Hassabis (@demishassabis) November 4, 2021

According to Hassabis, their aim is to “rethink” the process of developing new medicines using an AI-first approach:

“We believe that the fundamental use of advanced computing methods and artificial intelligence will help scientists take their work to a new level and significantly accelerate the drug discovery process.”

Isomorphic will build models that can predict how drugs interact with the body. The lab will leverage DeepMind’s developments, including the AlphaFold 2 protein-folding prediction AI tool.

At the same time, both labs will remain independent and will collaborate from time to time.

Hassabis added that the company does not intend to develop its own medicines. Instead, it will focus on developing partnerships with pharmaceutical companies and selling its models.

Earlier, DeepMind opened access to the database of human protein structures, created by the AlphaFold neural network.

In September, scientists developed an algorithm for identifying viruses that could jump from animals to humans.

In March, NVIDIA developed an artificial intelligence, accelerating the analysis of the human genome.

Subscribe to ForkLog News on Telegram: ForkLog AI — all the news from the world of AI!